Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intra-Cellular Therapies Inc ITCI

Healthcare
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical... see more

Recent & Breaking News (NDAQ:ITCI)

Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia

GlobeNewswire December 11, 2018

Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results

GlobeNewswire November 7, 2018

Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast

GlobeNewswire November 1, 2018

Investor Expectations to Drive Momentum within Tribune Media, Intra-Cellular Therapies, Icahn Enterprises, NVE, PetMed Express, and United Fire Group — Discovering Underlying Factors of Influence

GlobeNewswire October 25, 2018

Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease

GlobeNewswire October 23, 2018

Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting

GlobeNewswire October 17, 2018

Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer

GlobeNewswire October 16, 2018

Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia

GlobeNewswire September 28, 2018

Intra-Cellular Therapies to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 26, 2018

Intra-Cellular Therapies Appoints Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs

GlobeNewswire September 25, 2018

Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs

GlobeNewswire August 20, 2018

Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2018 Financial Results

GlobeNewswire August 2, 2018

Intra-Cellular Therapies to Host Second Quarter 2018 Financial Results Conference Call and Webcast

GlobeNewswire July 26, 2018

Intra-Cellular Therapies Announces Publication Highlighting ITI-214 Mechanism of Action and Describing Positive Results in Preclinical Models of Heart Failure

GlobeNewswire July 23, 2018

Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia

GlobeNewswire June 6, 2018

Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

GlobeNewswire May 31, 2018

Intra-Cellular Therapies to Present at the Jefferies 2018 Global Healthcare Conference

GlobeNewswire May 30, 2018

Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

GlobeNewswire May 29, 2018

New Research: Key Drivers of Growth for CSW Industrials, Cavco Industries, Intra-Cellular Therapies, Atrion, QAD, and A V Homes — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire May 24, 2018

Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

GlobeNewswire May 9, 2018